Buy Rating Justified by Alzamend Neuro's Promising Alzheimer's Treatments and Attractive Valuation
TipRanksApr 15 05:15 ET
Buy Rating for Alzamend Neuro Amid Promising Alzheimer's Drug Trials and Market Potential
TipRanksDec 19, 2023 05:06 ET
Promising Developments in Alzamend Neuro's Clinical Trials Bolster Buy Rating: A Focused Review on AL001's Potential in Mental Health Treatment
TipRanksOct 24, 2023 13:55 ET
Maxim Group Reaffirms Their Buy Rating on Alzamend Neuro (ALZN)
TipRanksJun 27, 2023 08:15 ET
Maxim Group Initiates Coverage On Alzamend Neuro With Buy Rating, Announces Price Target of $1.5
BenzingaApr 12, 2023 09:31 ET
Ascendiant Sticks to Their Buy Rating for Alzamend Neuro (ALZN)
TipRanksApr 5, 2023 08:41 ET
Alzamend Neuro (ALZN) Gets a Buy From Univest Securities
TipRanksOct 2, 2022 03:35 ET
Univest Securities Sticks to Their Buy Rating for Alzamend Neuro (ALZN)
TipRanksSep 14, 2022 09:00 ET
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN) and Alzamend Neuro (ALZN)
TipRanksAug 25, 2022 10:45 ET
No Data
No Data